Abstract
Interstitial lung disease is a rare but serious complication of epidermal growth factor receptor tyrosine kinase inhibitor therapy. Although our understanding of this phenomenon remains incomplete, recently there have been significant insights made into the mechanisms of injury, incidence, risk factors, and its clinical manifestations. Japanese patients appear to be at a higher risk (1.6%-3.5%) than patients in the rest of the world (0.3%), and other risk factors, such as coincident interstitial lung disease, concurrent chemotherapy, previous radiation, preexisting pulmonary fibrosis, and male sex, have been identified. In the majority of cases, the histopathology, the acute and often dramatic clinical presentation, and the radiographic findings resemble acute respiratory distress syndrome. Aside from immediate cessation of the offending agent, the treatment is largely supportive, although corticosteroids appear to be of benefit. The mortality remains high at approximately 30%-50%. We present a review of the incidence, risk factors, clinical manifestations, diagnosis, management, and outcome of this disorder.
| Original language | English (US) |
|---|---|
| Journal | Clinical Lung Cancer |
| Volume | 8 Suppl 1 |
| DOIs | |
| State | Published - Dec 2006 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Pulmonary and Respiratory Medicine
Cite this
Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. / Yoneda, Ken Y; Hardin, Kimberly A; Gandara, David R; Shelton, David K.
In: Clinical Lung Cancer, Vol. 8 Suppl 1, 12.2006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
AU - Yoneda, Ken Y
AU - Hardin, Kimberly A
AU - Gandara, David R
AU - Shelton, David K.
PY - 2006/12
Y1 - 2006/12
N2 - Interstitial lung disease is a rare but serious complication of epidermal growth factor receptor tyrosine kinase inhibitor therapy. Although our understanding of this phenomenon remains incomplete, recently there have been significant insights made into the mechanisms of injury, incidence, risk factors, and its clinical manifestations. Japanese patients appear to be at a higher risk (1.6%-3.5%) than patients in the rest of the world (0.3%), and other risk factors, such as coincident interstitial lung disease, concurrent chemotherapy, previous radiation, preexisting pulmonary fibrosis, and male sex, have been identified. In the majority of cases, the histopathology, the acute and often dramatic clinical presentation, and the radiographic findings resemble acute respiratory distress syndrome. Aside from immediate cessation of the offending agent, the treatment is largely supportive, although corticosteroids appear to be of benefit. The mortality remains high at approximately 30%-50%. We present a review of the incidence, risk factors, clinical manifestations, diagnosis, management, and outcome of this disorder.
AB - Interstitial lung disease is a rare but serious complication of epidermal growth factor receptor tyrosine kinase inhibitor therapy. Although our understanding of this phenomenon remains incomplete, recently there have been significant insights made into the mechanisms of injury, incidence, risk factors, and its clinical manifestations. Japanese patients appear to be at a higher risk (1.6%-3.5%) than patients in the rest of the world (0.3%), and other risk factors, such as coincident interstitial lung disease, concurrent chemotherapy, previous radiation, preexisting pulmonary fibrosis, and male sex, have been identified. In the majority of cases, the histopathology, the acute and often dramatic clinical presentation, and the radiographic findings resemble acute respiratory distress syndrome. Aside from immediate cessation of the offending agent, the treatment is largely supportive, although corticosteroids appear to be of benefit. The mortality remains high at approximately 30%-50%. We present a review of the incidence, risk factors, clinical manifestations, diagnosis, management, and outcome of this disorder.
UR - http://www.scopus.com/inward/record.url?scp=34249695579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249695579&partnerID=8YFLogxK
U2 - 10.3816/CLC.2006.s.011
DO - 10.3816/CLC.2006.s.011
M3 - Article
C2 - 17239288
AN - SCOPUS:34249695579
VL - 8 Suppl 1
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
ER -